Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IBI305 versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
CTR20182530Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by InnoCare Pharma. Started Feb 2019; status: active.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20182530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182530.